There is growing evidence that leptin is able to ameliorate Alzheimer's disease (AD)-like pathologies, including brain amyloid-b (Ab) burden. In order to improve the therapeutic potential for AD, we generated a lentivirus vector expressing leptin protein in a self-inactivating HIV-1 vector (HIV-leptin), and delivered this by intra-cerebroventricular administration to APP/PS1 transgenic model of AD. Three months after intra-cerebroventricular administration of HIV-leptin, brain Ab accumulation was reduced. By electron microscopy, we found that APP/PS1 mice exhibited deficits in synaptic density, which were partially rescued by HIV-leptin treatment. Synaptic deficits in APP/PS1 mice correlated with an enhancement of caspase-3 expression, and a reduction in synaptophysin levels in synaptosome preparations. Notably, HIV-leptin therapy reverted these dysfunctions. Moreover, leptin modulated neurite outgrowth in primary neuronal cultures, and rescued them from Ab 42 -induced toxicity. All the above changes suggest that leptin may affect multiple aspects of the synaptic status, and correlate with behavioral improvements. Our data suggest that leptin gene delivery has a therapeutic potential for Ab-targeted treatment of mouse model of AD.
INTRODUCTION
Alzheimer's disease (AD) is the most common form of dementia in the elderly. 1 Pathologic hallmarks of AD include senile plaques (of which b-amyloid peptide (Ab) is a major component), intracellular neurofibrillary tangles containing hyperphosphorylated tau, synapse dysfunction, progressive memory loss and eventual death of brain neurons. 2 Loss of connectivity, caused by neuronal death, and synapses is thought to underlie cognitive decline in AD. 3 There is a growing consensus that Ab is toxic to synapses. [4] [5] [6] Indeed, senile plaques are associated with a local loss of dendritic spines. [7] [8] [9] Leptin, an adipocyte-derived hormone, exhibits a large range of central and peripheral actions. 10 Leptin receptors have been identified in neurons in many brain regions, including the hippocampus, 11, 12 providing evidence for leptin's neuroprotective properties on proliferation and survival signaling. 13 Recent studies have demonstrated the potential beneficial effects of leptin in several transgenic animal AD models, namely modulation of the amount of Ab, and reduction of tau phosphorylation. [14] [15] [16] In addition, impaired behavior, memory and synaptic plasticity have been observed in leptin-deficient rodents. 17, 18 Importantly, clinical evidence shows alterations in the circulating levels of leptin in AD as patients with this disorder presents lower levels of leptin in the blood. 19, 20 In this study, we have used APP/PS1 mice displaying ADlike alterations [21] [22] [23] to investigate whether the cognitive and neuropathological disturbances associated with amyloidosis could be reversed by chronic treatment with leptin.
We have shown that overexpression of leptin by gene transfer with viral vectors resulted in a modulation in proliferation of neuronal progenitors and neuroprotection. 24 Recombinant lentiviral vectors are powerful tools for gene transfer to the central nervous system and hold great potential as a therapeutic gene therapy strategy for neurological disorders. 25 These lentiviral vectors are versatile tools because of both their relatively large cloning capacity and their ability to transduce non-dividing cells. Viral vector gene delivery of leptin via stereotactic injection into the central nervous system has proven to be a viable approach to treat transgenic mouse models of AD. Leptin treatment was administered to a 6-month-old APP/PS1 mice, and after 3 months of treatment, we found that leptin treatment reduced Ab accumulation, and alleviated synaptic alterations. In addition, we observed improvements in memory 3 months after vector delivery. These results suggest a novel and improved approach for delivery of leptin to the central nervous system for treatment of AD.
RESULTS

Leptin rescues behavioral deficits
For optimal gene delivery approach, we generated lentiviral vectors that were able to efficiently transfect most cell types. We inserted the cDNA of leptin into a lentiviral vector driven by the cytomegalovirus promoter. We previously reported that the resulting vector was able to transfect neuronal cells in vivo, and produced high levels of leptin expression. 24 Then, we determined whether HIV-leptin-treated APP/PS1 mice showed behavioral and cognitive recovery. Working memory was evaluated by measuring the rate of spontaneous alternations in the T-maze. This particular model of spatial memory was selected based upon its sensitivity of detection of cognitive deficits in AD mouse models. 26, 27 APP/PS1 mice showed a moderate deficit in this behavioral task, the baseline rate of spontaneous alternations being: 73.7 ± 4.9% in non-transgenic mice versus 59.3 ± 5.3% in APP/PS1 mice (P ¼ 0.068; Student's t-test). HIV-leptin treatment had only a partial effect on the performance of APP/PS1 mice; the alternation rate following chronic treatment was 66.3±5.1%. However, in APP/PS1 mice, the latency (seconds) to perform the correct choice was significantly increased compared with nontransgenic mice, whereas this time was reduced after HIV-leptin treatment (Po0.05; Figure 1a ).
Short-term memory was evaluated using a paradigm of nonspatial visual recognition memory, subjecting the animals to a 'novel object' recognition task, as previously described. 28 Retention in male APP/PS1 transgenic mice was significantly impaired relative to non-transgenic mice, whereas in HIV-leptintreated APP/PS1 mice the impaired cognition was completely restored (Po0.05; Figure 1b ). This result is similar to that of a recent study using different mouse model of AD, the TgCRND8 transgenic mice, and a different treatment consisting of a continuous delivery of leptin using a subcutaneous pump for 8 weeks. 16 Leptin reduces Ab plaque accumulation Previously, we did not detect a significant enhancement in endogenous leptin levels in plasma samples in APP/PS1 mice after HIV-leptin treatment (data not shown), suggesting a very restricted and subtle target, preventing possible peripheral side effects. In addition, there was no significant difference in glucose levels or body weight observed in leptin-or void vector (vv)-treated APP/PS1 mice, as described previously.
Leptin has been shown to reduce brain Ab levels in 6-monthold CRND8 transgenic mice following 8 weeks of treatment. 16 We demonstrated that Ab staining in the brain parenchyma of 6-month-old APP/PS1 mice was significantly reduced after 3 months of treatment with HIV-leptin (Figure 2a ). Stereological analysis of amyloid immunostaining in APP/PS1 mice treated with leptin showed a 34% decrease in the cerebral cortex, and a 22% decrease in the hippocampus ( Figure 2b ) compared with empty vector-treated APP/Ps1 mice. We also used thioflavin-S staining to detect amyloid deposits, and confirmed the reduction in amyloid deposits after HIV-leptin treatment (Figure 2c) .
To obtain a direct quantitative measurement of the Ab levels after HIV-leptin treatment, we performed an ELISA analysis of human Ab 40 and Ab 42 . The study revealed that APP/PS1 mice treated with HIV-leptin for 3 months had a significant decrease in human Ab 42 levels in the cerebral cortical and hippocampal regions (Table 1) , whereas human Ab 40 levels was only reduced in cerebral cortex (Table 1) .
We then investigated whether HIV-leptin treatment altered the processing of brain APP into Ab peptides. The amyloidogenic route was evaluated by testing the expression and the enzymatic activities of BACE1. We measured BACE1 expression in the cortical and hippocampal samples, using western blot (WB) assay. HIVleptin-treated mice had reduced the expression of BACE1 in cortical ( Figure 2d ) and hippocampal (Figure 2e ) samples, with similar levels to those observed in non-transgenic mice.
Because one proposed mechanism of Ab clearance is microglial Ab phagocytosis, we also tested the involvement of leptin in the regulation of activated microglia. Microglial cells were activated in mice transfected by HIV-leptin as an increased area showing tomato lectin positive cells in both cerebral cortex and hippocampus from HIV-leptin APP/PS1 mice was observed (Supplementary Figures a and b) . This microglial activation could be directly related to the decrease in the load of Ab, given the role of the microglia in the degradation of amyloid plaques.
Leptin modulates synaptic deficits Because leptin has been proposed to induce synaptic plasticity, [29] [30] [31] and in order to assess whether early cognitive decline in APP/PS1 mice and restoration after HIV-leptin treatment was associated with synaptic alterations, we measured synapse density in CA1 pyramidal neurons of the dorsal hippocampus in non-transgenic and APP/PS1 mice treated with HIV-vv or with HIV-leptin. The area studied in each of the 12 animals was 8820 mm 2 , and the total area analyzed in each experimental group was 35 280 mm 2 . Overall, there was a predominance of asymmetric synapses in all three experimental groups (average percentage of asymmetric synapses in (1) non-transgenic mice: 97.67±0.73%; (2) APP/PS1-HIV-vv: 97.48 ± 1.16%; (3) APP/PS1-HIV-leptin: 98.78 ± 1.10%). Therefore, we did not discriminate between synapse type (symmetrical or asymmetrical) in the estimation of the number of synapses per unit area. Also, we observed that most of the synaptic contacts occurred between axon terminals and dendritic spines, and less among axon terminals and dendritic shafts. A gross analysis of the ultrastructure showed that, compared with APP/PS1 mice, nontransgenic controls had an abundant number of synapses between axon terminals and dendritic spines. In addition, the morphology of the subcellular elements was well conserved in control animals, as expected, whereas the overall organization of the subcellular elements was somewhat less conserved in APP/PS1 Figure 1 . HIV-leptin treatment of APP/PS1 mice results in the attenuation of memory impairment. (a) Increased latencies in the spontaneous alternation of APP/PS1 mice in the T-maze were partially normalized after HIV-leptin treatment (3 months). (b) In the novel-object recognition task, recognition memory was expressed as exploratory preference in the retention test. The recognition index, representing exploratory preference, was reduced in APP/PS1 mice compared with non-transgenic mice (control), and recovered after HIV-leptin administration. Data are expressed as mean±s.e.m., *Po0.05, n ¼ 8 for non-transgenic control group, n ¼ 8 for APP/PS1 control group, n ¼ 12 for HIV-leptin-treated APP/PS1 mice. vv, void vector.
mice. The most prominent characteristics being the presence of excessively dilated and vacuolated dendrites, a decreased number of synaptic profiles, enlarged mitochondria, distended and irregular extracellular spaces, and a less compact and structured aspect of the tissue (Figure 3 , upper and middle panels). Finally, the ultrastructural morphology of HIV-leptin-treated APP/PS1 mice appeared to fluctuate between control and APP/PS1 mice. Extracellular spaces appear less distended and subcellular profiles appear more compact and less vacuolated. In addition, the number of synaptic profiles also seems to be greater compared with APP/PS1 mice ( Figure 3, lower panel) .
Given the absence of data about synaptic density in APP/PS1 transgenic mice, we first decided to compare the synaptic density between transgenic and non-transgenic mice. Analysis of the synaptic profiles showed a statistically significant reduction in the percentage of synapses in dendritic spines compared with the total percentage of synapses in APP/PS1 mice (Po0.05) ( Table 2) . Then, we investigated whether 3 months of gene therapy with Synapse loss has been associated with Ab-induced neurotoxicity in synaptosomes. 32 In addition, a recent study has demonstrated that caspase-3 activity is increased in Tg2576 hippocampal synapses, and correlates with spine degeneration and deficit in hippocampal-dependent memory. 33 Thus, we examined caspase-3 expression in cortical and hippocampal synaptosome preparations from non-transgenic and APP/PS1 mice with and without leptin treatment. We observed a marked increase in procaspase-3 expression in synaptosomes prepared from cerebral cortex of HIV-vv mice (Po0.01), which reduced after HIV-leptin treatment (Po0.05; Figures 4a and b). In these samples, the expression of active forms of caspase-3 (17 and 19 kDa) was undetectable by WB ( Figure 4a ). In the hippocampal synaptosome samples, the enhancement in procaspase-3 expression was not statistically significant (P ¼ 0.069) in APP/PS1 mice (data not shown). However, active forms of caspase-3 were markedly increased in these transgenic mice, showing a tendency toward reduction after HIV-leptin treatment (Figures 4c and d) .
These findings were also associated with an increased expression of procaspase-3 in the total tissue homogenates from cerebral cortex of APP/PS1 mice, whereas these effects were reverted after HIV-leptin treatment (Po0.05; Figures 4e and f). In the hippocampus, no significant differences were observed between experimental groups (data not shown). Notably, we found that procaspase-3 was more abundant in the synaptosomal fraction when compared with the total tissue homogenate. These findings suggest that caspase-3 is preferentially localized and selectively activated in the synaptic compartment, reinforcing the role of caspase-3 in synaptic dysfunction in AD. 33 In view of all these findings, we measured whether leptin was able to modulate Ab-induced cell death. Using the Cell Death Detection ELISA PLUS kit, we found an increased tendency in cell death in the cerebral cortex from APP/PS1 mice (P ¼ 0.06; Figure 4g ), and this effect was fully reverted after HIV-leptin treatment (Po0.05; Figure 4g ).
To provide additional evidence of the synaptic molecular modifications occurring in synaptosomes, we quantified the levels of synaptophysin, as pre-synaptic marker in the synaptosome preparations. We found that levels of synaptophysin were significantly reduced in synaptosome fractions prepared from cerebral cortex (Figures 5a and b) , and hippocampus of APP/PS1 mice as compared with non-transgenic mice (Figures 5c and d) . HIV-leptin treatment in APP/PS1 mice was able to increase these levels of synaptophysin in synaptosomal preparations from both brain areas (Figures 5b and d) . To determine whether leptin affects synaptophysin expression in neuronal cell cultures, cortical neurons were grown with the different treatments included in the media. Leptin treatment for 48 h produced a marked increase in synaptophysin expression, whereas Ab 42 tended to reduce this effect (Figures 5e and f) . When both molecules were added to the media, leptin was able to block the negative effects induced by Ab 42 on synaptophysin expression (Figures 5e and f) . These in vitro findings are consistent with the results from in vivo studies showing the effects of leptin on protein expression in synaptosomes of APP/PS1 mice, and support the direct involvement of Ab 42 in the process.
Previously, we confirmed that lentiviral administration did not generate any non-specific dysfunction in neurons. We compared the expression of caspase-3, and synaptophysin in intact (sham) APP/PS1 mice with that of HIV-vv-treated APP/PS1 mice. No differences were observed regarding the expression of these proteins in the cerebral cortex or hippocampus of APP/PS1 mice (data not shown).
Leptin modulates neurite length in neuronal cultures Previous studies have shown neurite degeneration caused by Ab in cultured neurons as one of the initial events in the process of neuronal death, 34 which ultimately leads to reduced neurite length. 35 As leptin rapidly enhances the motility and density of dendritic filopodia, neurite length and subsequently increases the density of hippocampal synapses, 29 we investigated the role of leptin in neurite degeneration evoked by Ab in cortical and hippocampal neuronal cell cultures. Thus, we studied the effect of both stimuli, leptin and Ab 42 , on neurite length through immunocytochemistry of calbindin-labeled cells, which allows to visualize mature neurons and the different types of neurites. Treatment of cortical neuronal cell cultures with both stimuli for 18 h produced modest changes. Only leptin induced an increase in the length of secondary neurites, whereas Ab 42 did not produce significant alterations (Figures 6a and c) . After 18 h, results obtained from hippocampal neurons were similar (Figures 6e  and g ). However, when neurite length was assessed 36 h after treatment addition, we observed that Ab 42 had produced a marked reduction (43%) in the total length of neurites from cortical neurons (control: 140.1 ± 30 mm; Ab 42 : 80.9 ± 2.1 mm). In addition, the reduction in neurite length induced by Ab 42 was completely antagonized by the administration of leptin (Figures  6b and d) . These alterations were mainly caused by changes in primary and secondary neurites. We also investigated the response of hippocampal neurons to Ab 42 , and found that the effects were less marked (Figures 6f and h) Figures 6f and h ). In summary, Ab 42 had a detrimental impact on both cortical and hippocampal neurons in culture reflected by a reduction in neurite length. This effect was prevented by leptin treatment.
DISCUSSION
Development of new approaches for the delivery of neuroactive peptides is of fundamental importance for advancing the therapeutics of AD. Here, we showed that leptin produced from a lentiviral vector regulated levels of Ab, and synaptic alterations in the brains of APP/PS1 mice. Our current study uses a new approach to examine this issue based on gene therapy as a viable approach of leptin delivery to the brain using a lentiviral vector. 24 Lentiviral vectors are valuable tools for neurobiology research because of their ability to transduce non-dividing cells, such as neurons. 36 This in vivo technique ensured a stable and effective overexpression of leptin, providing a more physiologic leptin delivery than is possible with direct infusion. Lentiviral vectors exhibit an inherent nontoxic capacity to migrate long distances, and a remarkable ability to modulate host brain cells. 19, 24, [37] [38] [39] In addition, leptin protein transduced in neurons was expressed in amounts sufficient to exert leptin-specific biological effects, Leptin gene therapy in APP/PS1 mice R Pé rez-González et al but insufficient for detection of alteration levels brain parenchyma or peripheral circulation, in accordance with previous studies using leptin gene therapy. 40, 41 These results demonstrate the utility of locally elevating the expression of leptin as a potential therapeutic approach for AD, although essential features are needed to ensure its translation to the clinic in the near future.
Lentiviral vector-mediated gene therapy offers many advantages compared with other viral systems and, as a therapeutic approach, is very attractive particularly for neurodegenerative disorders, including AD, as it can be delivered to the affected area, and one treatment offers long-term expression. After delivery into the nervous system they induce no significant immune responses, there are no unwanted side effects of the vectors per se to date, and manufacturing and safety testing for clinical applications are well advanced. However, significant issues remain in some areas of neural gene therapy including defining the optimum therapeutic gene(s), increasing the specificity of delivery, regulating expression of potentially toxic genes, and designing clinically relevant strategies.
Our findings indicated that 3 months gene therapy-mediated leptin administration reduced the accumulation of Ab deposits in APP/PS1 mice, coinciding with previous studies using another mouse model of amyloidosis and leptin treatment with a subcutaneous Alzet miniosmotic pump. 16 HIV-leptin treatment in 
(e) Asymetric synaptic contacts between spines (SP) and terminals (T). Note different dendritic shafts, one of them is longitudinally cut where a dendritic spine forms (dashed line). (f ) Asymetric synapse between a longitudinally cut dendrite (D) and a terminal (T).
In addition, a spine synapse (SP). Scale bar, 0.5 mm, n ¼ 4 for non-transgenic control group, n ¼ 4 for APP/PS1 control group, n ¼ 4 for HIV-leptin-treated APP/PS1 mice.
APP/PS1 mice resulted in the improvement in expression of synaptophysin in the cerebral cortex and hippocampus, and partial restoration of learning and memory impairment, in comparison with APP/PS1 mice treated with HIV-vv. Diverse evidences indicate that Ab oligomers detected within plaques induce synapse loss, 42 and memory deficits in the Tg2576 mouse model, 43, 44 and that leptin reduces brain amyloid burden. 16 More recently, the relationship between leptin and synaptic disruption has been documented as it was shown to prevent the Ab-induced deterioration of hippocampal long-term potentiation. 45 This study showed that leptin prevents Ab-induced AMPA-receptor removal from the synapses, thus preventing synapse molecular changes. In our present study, we show that apart from molecular changes, leptin has neuroprotective effects on the synapse structure, thus providing new insight into the coordinating mechanisms between leptin and Ab-induced neurodegeneration in AD. The characteristic sequence of events associated with Ab-induced neurodegeneration starts with the early loss of synaptic contacts, followed by neurite damage, neuronal degeneration, and, finally, neuronal death. 46, 47 We found that synapse density was significantly decreased in the CA1 layer of the hippocampus in APP/PS1 mice, and HIV-leptin treatment partially attenuated this impairment. In support of these results, the APP/PS1 transgenic mouse model showed a significant decrease in synaptophysin in synaptosomes compared with wild-type mice. Our experiments confirmed that Ab neurotoxicity is involved in this synaptophysin downregulation, as previously reported, 35 and a reversal of this decrease was observed in the HIV-leptin-treated APP/PS1 mice. We speculate that the neuroprotective effect of leptin against synapse loss is due to a decrease in the toxicity of Ab accumulation, probably by decreasing caspase-3 expression, whose upregulation in hippocampal CA1 dendritic spines led to a reduction in spine density. 33 The inhibitory effect of leptin on Ab accumulation is likely attributable to its inhibition of APP processing through the amyloidogenic pathway, modulating BACE expression, a major b-secretase involved in APP processing. In agreement with published data, 48 we found a modest difference in BACE expression in APP/PS1 mice compared with non-transgenic mice. This result is not surprising, as there is a progressive agedependent BACE expression that could be affecting the mechanism of APP processing. Although BACE1 levels were increased in 12-18-month-old APP/PS1 mice, 19, 49 no differences were observed in 6-month-old APP/PS1 mice compared with nontransgenic mice. 49 However, after 3 months of treatment with HIVleptin, we found that BACE expression was reduced in APP/PS1 mice compared with control transgenic mice.
In the brain of APP/PS1 mice, a discrete neuronal loss is associated with Ab plaques. 50 Consistent with these findings, we observed a slight increase in cell death in our model of transgenic mice, which was reversed in HIV-leptin-treated APP/PS1 mice. The neuroprotective effect of leptin seen in APP/PS1 mice is in line with previous reports showing protection against Ab-induced injury of primary cortical neuronal cultures. 45, 51, 52 Normal cognitive function largely depends on the proper connection between neurons, whereas treatment with Ab, reduces neurite outgrowth, 35 leptin promotes neurite outgrowth in hypothalamic, 53 and hippocampal neurons. 29 Therefore, we hypothesized that leptin might induce changes in neurite morphology, thereby contributing to the changes in hippocampal synaptic efficacy in AD. The finding that leptin completely antagonized the reduction in neurite length evoked by Ab confirms our hypothesis.
It has been demonstrated that leptin administration into the CA1 region of the hippocampus improves memory processing in mice performing T-maze foot-shock avoidance and step-down passive avoidance tests. 54 On the other hand, cognitive deficits are thought to be associated with leptin-deficiency in rodents, 18 and are also prevalent in humans with obesity-related diseases, such as type II diabetes. 55 As the decrease in the number of synapses is less marked in leptin-treated APP/PS1 mice compared with APP/PS1, it seems that leptin could be protecting from synapse loss, or inducing synaptogenesis, thereby preventing cognitive impairment. However, we cannot exclude the possibility that leptin improves memory through a mechanism other than the decrease of Ab accumulation, because adult neurogenesis has Total neurite length, and neurite length of each order were estimated in photomicrographs of calbindin þ hippocampal neurons 18 h (g), and 36 h (h) after treatments, and using a stereological procedure. Data are expressed as mean ± s.e.m., *Po0.05, n ¼ 3 independent experiments.
Leptin gene therapy in APP/PS1 mice R Pé rez-González et al been proposed to mediate hippocampal-dependent learning and the therapeutic actions of antidepressants, 56,57 and we have recently reported that leptin stimulates proliferation of newly formed hippocampal neurons in APP/PS1 mice. 24 In summary, our experimental approach using a lentiviral viral vector allows the diffusion of the therapeutic factor, leptin, in the brain of a mouse model of AD. Our study demonstrates that leptin not only can ameliorate brain Ab accumulation, but also synaptic, cognitive, behavioral and Ab-induced neuronal network dysfunctions. Our findings indicate that targeting the aberrant network activity with leptin or related drugs might be of therapeutic benefit in the prevention or treatment of AD.
MATERIALS AND METHODS
Lentiviral vectors
Lentiviral vectors were produced using a four-plasmid transfection system, as described previously. 24 Briefly, a cDNA coding for mouse leptin was subcloned in the XbaI-BamHI site of the pRRLsin18.PPT.CMV.eGFP.Wpre transfer vector, with a small segment of the viral hemagglutinin coat protein as an epitope tag (HA). Empty vector (no insert) was used as a control (void vector, HIV-vv) in all experiments. Packaging, purification and titter determination of the lentivirus were performed as described previously. 37 The packaging construct and the vesicular stomatitis virus G protein envelope included the pCMVDR-8.92, pRSV-Rev and pMD.G plasmids, respectively. The transfer vector (13 mg), the envelope (3.75 mg) and the packaging plasmids (3.5 mg) were co-transfected with calcium phosphate in 293 T cells (5 Â 106 cells/dish) cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco, Carlsbad, CA, USA) with 10% FCS, 1% glutamine and 1% penicillin/streptomycin. Medium was changed 2 h prior to transfection, and replaced after 24 h. Conditioned medium was collected 24 h later, cleared (1000 rpm/5 min) and concentrated E100-fold (19 000 rpm/1.5 h). The pellet was resuspended in phosphate-buffered saline with 1% bovine serum albumin, and the virus stored at À 80 1C. Viral titter was determined by HIV-1 p24 ELISA (PerkinElmer, Wellesley, MA, USA).
Animals
We used the double-transgenic APP/PS1 mice, B6.Cg-Tg (APPSwe, PSEN1dE9)/J mouse line (Jackson Laboratory, Bar Harbor, ME, USA: stock no. 005864), which expresses human APP (Swedish mutation) and presenilin 1 with a deletion in exon 9 (APP/PS1). A total of 20 six-monthold double transgenic APP/PS1 male, and 8 age-matched non-transgenic male littermates were used as controls. Vector suspensions (2 ml per mouse) were stereotaxically injected in each lateral ventricle (brain coordinates are expressed as mm from bregma: 0.6 posterior, 1.1 lateral and 2 ventral) with a 10 ml syringe at a rate of 1 ml min À 1 . Animals were weighed at the beginning and at the end of experimental period (3 months). After 3 months of treatment, when mice were 9 months of age, animals were deeply anesthetized and transcardially perfused either with saline for biochemical analysis, or 4% paraformaldehyde in 0.1 M phosphate buffer (PB), pH 7.4 for immunohistochemical analysis. All animals were handled and cared for according to the Council Directive 2010/63/UE of 22 September 2010.
Behavioral testing
After adaptation to human handling, behavioral tests were conducted in APP/PS1 and non-transgenic mice over 11-day period, as previously described. 28 On each study day, spontaneous alternation, tested with a T-maze, a behavioral test of spatial memory, 27 was the first parameter evaluated, followed by the object recognition test (days 10 and 11), a test of non-spatial visual recognition memory. 58 In the T-maze, the number of alternations and errors (entries to previously visited arms), and the time to complete each session (latency) were recorded. In the object recognition test, the recognition index, was defined as the ratio of the time spent exploring the novel object over the time spent exploring both objects in percentage, and was used to measure non-spatial memory.
Primary neuronal cultures
Primary neuronal cultures from the cerebral cortex and hippocampus, obtained from Wistar rat embryos on prenatal day 17 (E17), were performed as previously described. 12 Briefly, pregnant female patients were anesthetized with isoflurane (Forane, Baxter, Deerfield, IL, USA), and subjected to cesarean section in order to remove fetuses and their brains. Cerebral cortex and hippocampus were dissected, incubated for 5 min in Neurobasal medium (Gibco) at 37 1C and mechanically dissociated during 5 min and finally centrifuged at 210 g for 5 min at 21 1C. The cells were suspended in Neurobasal medium (Gibco) supplemented with B27 (Gibco), 2 mM glutamine, 100 U/ml penicillin, 100 mg ml À 1 streptomycin and 0.25 mg ml À 1 amphotericin B, and plated at a density of 2.5 Â 10 5 cells per square centimeter onto poly-Lysine (1 mg ml À 1 ; Sigma, St Louis, MO, USA)-coated multi-well plates. The cultures were maintained at 37 1C in a humidified atmosphere containing a 5% CO 2 and cultivated for 7 days prior to experimentation. Then, cultures were incubated in fresh medium with or without 100 nM leptin, alone or in combination with 5 mg ml À 1 oligomeric Ab 42 . Ab 42 was previously dissolved in acetic acid 0.1 M, and then was dissolved in sterile distilled water as reported previously. 19 Determination of neurite outgrowth Cortical and hippocampal neuronal cultures were seeded at 5 Â 10 4 cells cm À 2 on poly (lysine)-coated 24-well plates. Eighteen and 36 h after treatment (100 nM leptin, and 5 mg ml À 1 oligomeric Ab 42 ), cells were fixed with 2% paraformaldehyde, and labeled with an anti-calbindin antibody. Images were obtained using a Zeiss LSM 510 Meta scanning laser confocal microscope with a Â 40 objective, converted to 8-bit grayscale images for analysis. The term 'neurite' refers to any projection from the cell body of a neuron, which can either be an axon or a dendrite. Processes with lengths equivalent to one or more diameters of a cell body were counted as neurites. Morphometric analysis was performed with ImageJ 1.43 u software (National Institute of Health, USA) with the NeuronJ plug-in. Morphological analysis of neurite length was performed as described previously, 12 based on a method adapted from a study by Arendt et al.
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A centrifugal ordering system was used to establish branch or neurite order in a neuron, and branch order was taken into consideration when calculating total neurite length, as well as the length of neurite of each order. The average neurite length was calculated and subsequently analyzed using a two-way ANOVA. At least 30 neurons were examined for each group.
Immunohistochemistry
Fixed brains were cut on a vibratome (Leica Microsystems, Barcelona, Spain) at 50 mm, tissue sections were collected in cold PB 0.1 M, and incubated overnight with primary antibodies at 4 1C. To detect Ab deposits, brain sections from APP/PS1 mice were pre-incubated with 88% formic acid and immunostained as previously described. 60 The following primary antibodies were used: mouse anti-Ab (1:500, MBL, Nagoya, Japan), rabbit anti-Ab (1:500, Millipore, Billerica, MA, USA). And the secondary antibodies were: biotinylated anti-mouse IgG (1: 400, Vector Laboratories, Burlingame, CA, USA), and Texas Red goat anti-rabbit IgG antibody (1:1000, Jackson Immunoresearch, West Grove, PA, USA). Immunostaining of microglial cells was performed with rodhamine-labeled tomato-lectin (Vector Laboratories). Images were captured using a Zeiss LSM 510 Meta scanning laser confocal microscope (Carl Zeiss Microimaging, GmbH, Gö ttingen, Germany). Ab þ area was analyzed stereologically as described previously, 60 and plaque burden was expressed as percentage of brain area stained with Ab. Pictures were taken using light microscopy (Zeiss microscope; Carl Zeiss Microimaging, GmbH) at a magnification of Â 10. Three or four areas were sampled within each section and semiquantitative analysis of labeled signal was performed using NIH Image J software. Amyloid deposits in parenchyma were also evaluated using Thioflavin S (ThS) staining.
Synaptosome preparation
Hippocampal tissue was homogenized in homogenization buffer containing 320 mM sucrose, 4 mM HEPES (pH 7.4), 1 mM EGTA, 1 mM PMSF and protease inhibitor cocktail (Roche, Madrid, Spain) in a glass Dounce tissue grinder, as previously described. 33 The homogenate was centrifuged at 1000 g for 10 min and the resulting supernatant was centrifuged at 12 000 g for 15 min. The pellet was resuspended in homogenization buffer and centrifuged at 13 000 g for 15 min to obtain the final pellet containing the synaptosome-enriched fraction.
Biochemical measurements
For WB analysis, samples were homogenized in lysis buffer containing 150 mM NaCl, 20 mM Tris-HCl (pH 7.4), 1% Nonidet P-40, 1 mM PMSF and Leptin gene therapy in APP/PS1 mice R Pé rez-González et al protease inhibitor cocktail (Roche), and then 2% SDS-containing buffers, electrophoresed and blotted. Antibodies used included: rabbit anti-BACE1 (1:1000; Sigma), rabbit anti-caspase-3 (1:1000, Cell signaling, Danvers, MA, USA) and mouse anti-synaptophysin (1:1000, Millipore). Mouse leptin levels in plasma samples from APP/PS1 and non-transgenic mice were determined using the Quantikine Mouse Leptin Immunoassay (R&D Systems; Minneapolis, MN, USA). Blood glucose was measured after 12 h fasting using a glucometer (Accu-Chek, Roche). Levels of human soluble Ab 40 and Ab 42 in cerebral cortex and hippocampus fractions from APP/PS1 mice were determined with human-specific ELISA kits (Biosource, Invitrogen, Camarillo, CA, USA), according to the manufacturer's instructions. The final Ab 40 and Ab 42 values were determined following normalization to total protein levels. For cell death quantification, DNA fragmentation in cortical samples of APP/ PS1 mice undergoing apoptosis was detected using a Cell Death Detection ELISA PLUS kit (Roche Diagnostics), according to the manufacturer's protocol.
Electron microscopy
Mice were intracardially perfused with saline solution followed by 2% paraformaldehyde and 3.8% acrolein in 0.1 M PB, pH 7.4. The brains were removed and post-fixed overnight in 2% paraformaldehyde in 0.1 M PB. Coronal 500 mm thick sections containing the hippocampus were cut on a Series 3000 vibratome (Technical Products International, St Louis, MO, USA).
With the help of a magnifying glass, 1.0-1.5 mm 3 trapezoid shaped blocks of tissue of the hippocampal CA1 area were cut with a scalpel, for a total of three blocks of tissue per mouse. The 36 tissue blocks were placed in individual, coded and blind to condition glass vials, post-fixed in 1% osmium tetroxide in 0.1 M PB for 2 h, dehydrated in a series of cold graded ethanols and propylene oxide, incubated for 24 h in a 1:1 mixture of propylene oxide and epoxy resin (Embed 812; Electron Microscopy Sciences, Fort Washington, PA, USA) and then in 100% epoxy resin for 12-15 h. Each block was then transferred to flat-ended embedding capsules containing epoxy resin. The position of each one of the three tissue blocks belonging to each mouse was adjusted using a wooden stick in order to ensure that each had a different orientation relative to the other. The tissue was polymerized at 60 1C for at least 48 h, after which blocks were trimmed, ultrathin-sectioned on an ultramicrotome and collected on 400 mesh copper grids and analyzed under a Jeol JEM 1010 electron microscope at 80 kV coupled to a digital camera (GATAN BioScan Gatan Inc., Mü nchen, Germany).
Thirty micrographs at 25 K magnification were taken of each of the 36 copper grids in a diagonal fashion by rows from corner to corner of the mesh. To select the micrographs that were going to be analyzed, we conducted a random sampling, blind as to condition, in which one out of every three micrographs from every grid was selected. The total number of synapses, the profiles where these synapses occurred (dendritic shafts or spines) and the relationship between the number of shaft synapses and spine synapses were counted using ImageJ software, version 1.46 using an unbiased counting frame area of 20 um 2 . The classification of cellular elements was based on the descriptions made by Peters et al. 61 Asymmetric synapses were identified by the presence of thick postsynaptic densities, whereas symmetric synapses were identified by the presence of thin pre-and postsynaptic specializations. In addition, synapses were classified as shaft synapses, that is, those occurring on the surface of a dendrite, or spine synapses, that is, those occurring at the bulbous end of a relatively short (o2 mm) protrusion separated from the dendrite by a neck or narrower region.
